Notice: This company has been marked as potentially delisted and may not be actively trading. AVROBIO (AVRO) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period L'action TECX atteint un sommet sur 52 semaines à 47,99$ dans un contexte de hausse des marchésNovember 13, 2024 | fr.investing.comPromising Potential and Strong Safety Profile Drive Buy Rating for Tectonic TherapeuticNovember 13, 2024 | markets.businessinsider.comTectonic Therapeutic: Promising Phase 1a Results and Strong Financial Health Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comL'action TECX atteint un plus haut de 52 semaines à 38,14$ dans un contexte d'optimisme du marchéOctober 25, 2024 | fr.investing.comLe titre TECX atteint un plus haut de 52 semaines à 34,54$ dans un contexte de rallye boursierOctober 15, 2024 | fr.investing.comTD Cowen Sticks to Their Buy Rating for Tectonic Therapeutic (TECX)September 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tectonic Therapeutics Following Promising TX45 Trial Results and Future CatalystsSeptember 21, 2024 | markets.businessinsider.comL'action TECX atteint un sommet de 52 semaines à 19,68$ dans un contexte d'optimisme du marchéSeptember 19, 2024 | fr.investing.comBuy Rating Affirmed on Tectonic Therapeutics’ TX45 for Promising Clinical AdvancementsAugust 16, 2024 | markets.businessinsider.comTectonic Therapeutic: Analyzing Its Post-Merger Valuation And ProspectsAugust 4, 2024 | seekingalpha.comTectonic Therapeutic Inc (TECX)August 2, 2024 | investing.comJuly M&A deals: Eli Lilly, Desktop Metal and Eastern Bank.August 1, 2024 | bizjournals.comGlobal Gene Therapy Strategic Research Report 2024-2030: Availability of Novel Therapies Drive Market GrowthJuly 31, 2024 | uk.finance.yahoo.comTectonic Therapeutic Inc TECXJuly 31, 2024 | morningstar.comTectonic Therapeutic Announces US IND Clearance for Lead Program, TX45July 31, 2024 | tmcnet.comWhy Is Avrobio (AVRO) Stock Moving Today?June 20, 2024 | investorplace.comAVROBIO Stock Scheduled to Reverse Split on Thursday, June 20th (NASDAQ:AVRO)AVROBIO, Inc. (NASDAQ:AVRO - Free Report) shares are going to reverse split before the market opens on Thursday, June 20th. The 1-12 reverse split was announced on Thursday, June 20th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, June 20th.June 18, 2024 | marketbeat.comAVROBIO, Inc. (NASDAQ:AVRO) Short Interest UpdateAVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 139,600 shares, a decrease of 23.1% from the May 15th total of 181,600 shares. Approximately 0.4% of the company's shares are short sold. Based on an average daily volume of 225,500 shares, the short-interest ratio is presently 0.6 days.June 14, 2024 | marketbeat.comTectonic Therapeutic Appoints Daniel Lochner as Chief Financial OfficerJune 3, 2024 | businesswire.comShort Interest in AVROBIO, Inc. (NASDAQ:AVRO) Increases By 11.3%AVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 181,600 shares, an increase of 11.3% from the April 30th total of 163,200 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 219,000 shares, the days-to-cover ratio is currently 0.8 days.June 1, 2024 | marketbeat.comBraden Michael Leonard Buys 469,753 Shares of AVROBIO, Inc. (NASDAQ:AVRO) StockMay 16, 2024 | insidertrades.comAVROBIO, Inc. (AVRO) Stock Price, News, Quote & History - Yahoo FinanceMay 16, 2024 | finance.yahoo.comUn cadre d'Avrobio achète des actions d'une valeur de plus de 970 000 dollarsMay 15, 2024 | fr.investing.comInsider Buying: AVROBIO, Inc. (NASDAQ:AVRO) Major Shareholder Acquires 469,753 Shares of StockAVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) major shareholder Braden Michael Leonard purchased 469,753 shares of the firm's stock in a transaction dated Monday, May 13th. The stock was purchased at an average cost of $1.25 per share, with a total value of $587,191.25. Following the acquisition, the insider now directly owns 4,471,380 shares in the company, valued at $5,589,225. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.May 15, 2024 | marketbeat.comShort Interest in AVROBIO, Inc. (NASDAQ:AVRO) Expands By 19.0%AVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 163,200 shares, a growth of 19.0% from the April 15th total of 137,200 shares. Based on an average daily volume of 214,200 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.4% of the company's shares are short sold.May 14, 2024 | marketbeat.comAVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVROMay 9, 2024 | businesswire.comDeal watch: Biopharma M&A more than doubled in Q1April 22, 2024 | bizjournals.comShort Interest in AVROBIO, Inc. (NASDAQ:AVRO) Rises By 14.6%AVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 143,200 shares, a growth of 14.6% from the March 15th total of 125,000 shares. Currently, 0.4% of the company's shares are sold short. Based on an average daily volume of 299,800 shares, the days-to-cover ratio is currently 0.5 days.April 14, 2024 | marketbeat.comAVROBIO Inc.March 26, 2024 | wsj.comAVROBIO (AVRO) Scheduled to Post Quarterly Earnings on ThursdayAVROBIO (NASDAQ:AVRO) will be releasing earnings on Thursday, March 21.March 20, 2024 | marketbeat.comAVROBIO, Inc. (NASDAQ:AVRO) Short Interest Down 30.3% in FebruaryAVROBIO, Inc. (NASDAQ:AVRO - Get Free Report) saw a large decline in short interest in February. As of February 15th, there was short interest totalling 126,500 shares, a decline of 30.3% from the January 31st total of 181,500 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 287,600 shares, the short-interest ratio is currently 0.4 days.March 1, 2024 | marketbeat.comAVRO Apr 2024 2.500 callFebruary 23, 2024 | ca.finance.yahoo.comAVRO May 2024 2.500 callFebruary 18, 2024 | finance.yahoo.comAVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVROFebruary 14, 2024 | businesswire.comShareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with TectonicJanuary 31, 2024 | stockhouse.comFive things: Vertex's new drug, a reverse merger, and how are you doing?January 31, 2024 | bizjournals.comAvrobio Inc Announces Executive Team Changes and AppointmentsJanuary 31, 2024 | msn.comAvrobio to take Watertown biotech public via reverse mergerJanuary 30, 2024 | bizjournals.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCALJanuary 30, 2024 | stockhouse.comAvrobio to buy 100% equity interests of Tectonic TherapeuticJanuary 30, 2024 | msn.comAvrobio Shares Dive 17% After Tectonic Therapeutic DealJanuary 30, 2024 | marketwatch.comAVROBIO and Tectonic Therapeutic Announce MergerJanuary 30, 2024 | finance.yahoo.comTrading was temporarily halted for "AVRO" at 07:01 AM with a stated reason of "News pending."January 30, 2024 | marketbeat.comAvrobio Stock (NASDAQ:AVRO), Analyst Ratings, Price Targets, PredictionsDecember 20, 2023 | benzinga.comMizuho Downgrades AVROBIO (AVRO)December 19, 2023 | msn.comAvrobio Stock (NASDAQ:AVRO) Dividends: History, Yield and DatesDecember 19, 2023 | benzinga.comAvrobio just downgraded at Mizuho, here's whyDecember 18, 2023 | realmoney.thestreet.comAvrobio Inc AVRONovember 14, 2023 | morningstar.comPotential Growth and Strategic Alternatives: Reasons Behind Zhu’s Buy Rating for AvrobioNovember 14, 2023 | markets.businessinsider.comIs AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?November 8, 2023 | finance.yahoo.com Get AVROBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss. Click Here to get the full details about Crypto’s Hidden Gem AVRO Media Mentions By Week AVRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVRO News Sentiment▼0.000.60▲Average Medical News Sentiment AVRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVRO Articles This Week▼01▲AVRO Articles Average Week Get AVROBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ocugen News Today Inhibikase Therapeutics News Today Lexeo Therapeutics News Today Fate Therapeutics News Today Tenaya Therapeutics News Today Molecular Partners News Today SOPHiA GENETICS News Today Inhibrx News Today Cardiff Oncology News Today Compass Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVRO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVROBIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AVROBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
